Krystal Biotech to Present Advancements at Cantor Global Healthcare Conference

PITTSBURGH, Sept. 03, 2026 /CourierPR/ -- Krystal Biotech, Inc., a fully integrated, global biotechnology company, will participate in the 2026 Cantor Global Healthcare Conference, set for September 10, 2026, in New York. The company’s management will host a fireside chat at 3:55 pm ET and conduct investor meetings throughout the day.

During the conference, Krystal Biotech will present its advancements in genetic medicines, focusing on treatments for diseases with significant unmet medical needs. The company’s first commercial product, VYJUVEK®, has already made history as the first redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The presentation will be available via webcast starting at 3:55 pm ET on the company’s website.

Krystal Biotech continues to expand its pipeline, with multiple preclinical and clinical-stage investigational genetic medicines in development. The company is headquartered in Pittsburgh, Pennsylvania, and invites investors and the public to visit its website for more information or follow the company on LinkedIn and X.

The webcast of the presentation will be accessible on the Investors section of Krystal Biotech’s website, providing a platform for stakeholders to engage with the company’s leadership.